Celyad SA (CYAD) Reports First Complete Response in Relapsed Refractory AML Patient in THINK Trial
Tweet Send to a Friend
Celyad (NASDAQ: CYAD) today announces exciting early clinical results of the first dose-level in the hematological arm of its THINK ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
